



Serum Neopterin as a Novel Marker for Carotid Artery Stenosis in Community Subjects

Huanquan Liao^{1*}, Zhichao Yan^{2*}, Hongxuan Wang³, Hua Hong^{4##}

¹Department of Neurology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China

²Department of Ophthalmology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China

³Department of Neurology, The Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

⁴Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Email: *sumsdiy@163.com

How to cite this paper: Liao, H.Q., Yan, Z.C., Hong, H. and Wang, H.X. (2018) Serum Neopterin as a Novel Marker for Carotid Artery Stenosis in Community Subjects. *Open Access Library Journal*, 5: e5083.

<https://doi.org/10.4236/oalib.1105083>

Received: November 16, 2018

Accepted: December 1, 2018

Published: December 4, 2018

Copyright © 2018 by authors and Open Access Library Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

<http://creativecommons.org/licenses/by/4.0/>



Open Access

Abstract

Background: Carotid artery stenosis (CAS) is one of the major high-risk mechanisms of stroke. Neopterin, an immune modulator secreted by macrophages, has been reported to be elevated in patients with cerebrovascular disease. However, an association between serum neopterin level and CAS has not been firmly established. **Objective:** To investigate the cross-sectional relationship between serum neopterin levels and CAS assessed by ultrasound. **Methods:** The study participants were volunteers in a community-based cohort aiming to prevent stroke in Guangzhou. Bilateral carotid artery ultrasonography was performed to assess the carotid atherosclerosis. After participant criterion screening and random sampling, finally 140 subjects were studied in our present study. Enzyme-linked immunosorbent assay was performed to measured serum neopterin concentrations. **Results:** Neopterin level in the CAS and control group was 5.4 (3.3 - 7.3) nmol/L and 4.6 (3.6 - 5.4) nmol/L respectively, with a significant difference ($P < 0.05$). After multivariate adjusted, neopterin levels remained an independent factor. With per 1.0 nmol/L (approximately 1 IQR) increasing, the OR value was 1.84 (95% CI: 1.25 - 2.71, $P < 0.05$). ROC curve of serum neopterin concentrations for the prediction of CAS revealed that the area under curve was 0.665 ($P < 0.01$). The cutoff value of 5.1 nmol/L had a sensitivity of 68.6% and specificity of 61.5% in detecting CAS. **Conclusion:** These findings demonstrate that circulating neopterin level is increased in subclinical carotid atherosclerosis population with CAS and reinforce the key roles of inflammatory response in the pathogenesis.

Subject Areas

Neurology

*These authors contributed equally to this work.

Keywords

Neopterin, Carotid, Carotid Artery Stenosis, Ultrasound

1. Introduction

Stroke remains one of the most devastating neurological diseases, often causing death, or gross physical impairment [1]. Carotid artery atherosclerosis (CAA) is one of the major high-risk mechanisms of stroke [2]. Epidemiologic estimates of first-time ischemic stroke attributable to CAA vary, but range from roughly 7 to 18% of all incident strokes [3] [4]. Cerebral infarction may result from the reduction in cerebral perfusion pressure that occurs distal to a tight carotid artery stenosis (CAS) or occlusion [5] [6]. While an embolism may also contribute, the association of border zone infarcts with CAS emphasizes the significance of hemodynamic disturbance in the pathogenesis of these types of infarct [6]. Numerous publications from recent years indicate a significant contribution of inflammatory factors to the development and progression of atherosclerosis [7]. Atherosclerotic lesions in the carotid arteries have been associated with increased serum levels of different inflammatory markers, such as C-reactive protein and fibrinogen [8] [9]. Inflammatory cytokines enter the circulation in soluble form. The concept of the involvement of inflammation in atherosclerosis has validated the adoption of inflammatory biomarkers for cerebrovascular risk stratification and prediction [10]. Neopterin is a pteridine derivative of the body fluids which is biologically stable, mainly produced by macrophages stimulated by γ -IFN which is secreted by activated T cells lymphocytes [11], and is a specific marker for activated mononuclear macrophages [12]. In fact, elevated neopterin levels have been reported in patients with coronary artery disease compared with controls [13] [14]. Astonishingly, an association between serum neopterin level and CAS has not been firmly established. In this context, we hypothesized that neopterin may be related to CAS. Thus, the current study sought to achieve this objective by measuring circulating serum neopterin levels in community subjects and investigating the cross-sectional relationship between serum neopterin levels and CAS assessed by ultrasound.

2. Materials and Methods

2.1. Participant Enrollment, Screening, and Selection

Study participants were residents living in Nonglin community in the center of Guangzhou, China. Residents were recruited in a community-based cohort aiming to prevent stroke by the organization of Department of Neurology, the First Affiliated Hospital, Sun Yat-sen University from July 2008 to December 2008. Residents who were volunteers, aged from 46 to 75, and willing to be reexamined in future were eligible. Residents were excluded if they lived in other districts, refused to complete necessary questionnaires and examinations in the study or had malignant tumors, acute myocardial infarction, and other critical

illnesses which would possibly affect the follow-up in the future. Altogether 962 participants were recruited. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University and all participants gave written informed consent of the study. In the present study, participants were further excluded if they had diseases which corroboratively or potentially affect the function of the immune system including cardiovascular disease, cerebrovascular disease, chronic renal failure, chronic liver insufficiency, blood diseases, asthma, acute infectious diseases, or autoimmune diseases. After the present study criterion screening, 534 participants were eligible for our present study. Among these participants, there were 183 (34.3%) subjects with CAS, other 351 (65.7%) subjects without CAS were taken as controls. Eventually, random sampling was used to select the sample for the study. Finally 70 participants were respectively selected from the CAS and control groups. Totally 140 subjects were studied in our present study.

2.2. Medical and Physical Risk Factors

Demographic variables, histories of previous diseases, cigarette smoking, and alcohol consumption were obtained by well trained investigators by face to face interview in clinics using a standardized questionnaire. Cigarette smoking was defined as the subject had smoked more than 1 cigarette per day for more than half a year. Alcohol consumption was defined as the subject had drunk any kind of alcohol drinks more than once a week regularly for more than half a year. Previous histories of hypertension, diabetes, hyperlipidemia, heart disease or stroke were defined if the subject had been diagnosed with the disease in hospital before or had used medications regularly. Waist and hip circumference, weight and height were measured and then waist hip ratio (WHR) was calculated. Body mass index (BMI) was calculated as weight (kg) divided by the square of height (m²). Blood pressure was measured with a mercury sphygmomanometer in the morning.

2.3. Biological Risk Factors

Fasting venous blood samples for fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), high-sensitivity C-reaction protein (hs-CRP), and uric acid (UA) were collected in the morning and then analyzed by the enzyme method in autoanalyzing machine. The coefficients of variance of repeated measurements of the chemistry tests were 1.0% to 1.6%.

2.4. Ultrasound Assessment of CAS

Carotid ultrasound measurements were performed with one B mode ultrasound system, APLIO XU equipped with a 7.5 MHz linear array transducer (TOSHIBA, USA) by 2 experienced vascular sonographers. Subjects were examined in supine position with their necks extended. The three bilateral defined locations including common carotid (20 mm proximal to the bifurcation), carotid bifurcation and internal carotid artery (ICA, 10 mm distal to bifurcation) were measured

longitudinally and transversely. The scan and measurements were performed according to internationally recognized guidelines [15]. Intima-media thickness (IMT) was measured as the distance between the two parallel echogenic lines on the far wall of artery in longitudinal plane image frozen in the screen by electronic calipers [16]. Plaque was defined as localized thickening of IMT ≥ 1.3 mm which did not uniformly involve the whole wall of carotid artery [17]. Classification of ultrasound plaque appearance was performed independently from the videotape by 1 single operator blinded to all other data. 3 categories were classified as 1) no plaques; 2) echogenic plaques; 3) echolucent plaques. Echolucent plaques are mainly composed by the deposition of cholesterol, necrosis tissue and plaque bleeding, a type of plaque with instability [18]. The carotid stenosis measurements were performed according to internationally recognized guidelines [8]. The peak systolic velocity (PSV) and end diastolic velocity (EDV) were measured in the common and internal carotid arteries, and the degree of stenosis was then calculated according to St. Mary's Ratio which is the ratio of the PSV in the internal carotid arteries, a value that increases with degree of stenosis, divided by the EDV in the distal common carotid artery, a value that decreases with increasing resistance in the internal carotid arteries due to stenosis (see **Table 1**) [19]. We had assessed interobserver reproducibility of CAS detection by repeated scans on several randomly selected participants. The kappa value for the agreement of CAS was 0.738 ($P < 0.01$), which was acceptable.

2.5. Measurements of Serum Neopterin

Circulating serum neopterin concentrations were measured using a commercially available solid phase enzyme-linked immunosorbent assay (ELISA) kit (IBL, Hamburg, Germany) based on the basic principle of a competitive ELISA. An unknown amount of antigen in the sample and a fixed amount of enzyme labelled antigen compete for the antibody-binding sites (rabbit-anti-neopterin). Both antigen-antibody complexes bind to the wells of the microtiter strips coated with a goat-anti-rabbit antibody. Unbound antigen is removed by washing. The intensity of the color developed after the substrate incubation is inversely proportional to the amount of antigen in the sample. Results of samples can be determined directly using the standard curve. In our study, inter-assay and intra-assay coefficients of variation were $<5.9\%$ and $<8.9\%$ respectively.

Table 1. Calculation of St. Mary's ratio.

St. Mary's Ratio	ICA Stenosis (%)
<8	<50
8 - 10	50 - 59
11 - 13	60 - 69
14 - 21	70 - 79
22 - 29	80 - 89
>30	>90 but less than near occlusion
Variable	Near occlusion

2.6. Statistical Analysis

Analysis of normality of the continuous variables was performed with the Kolmogorov-Smirnov test. Results for continuous variables normally distributed were expressed as mean value \pm standard deviation (SD) and non-normally distributed (neopterin levels) was presented as median value (lower quartile-upper quartile). Dichotomized or categorized variables were described as numbers and proportions. In univariate analysis, continuous variables normally distributed were compared by student's t test. Continuous variable non-normally distributed was compared by nonparametric Mann-Whitney U test. Dichotomized or categorized variables were compared by Chi-square tests. The correlation between serum neopterin and hs-CRP levels was assessed using Pearson's coefficient correlation analysis. In order to adjust the confounding factors which is significant in univariate analysis, binary logistic regression analysis was performed to investigate the risk factors for CAS. Odds ratio (OR) was calculated by logistic model. The receiver operating characteristic (ROC) curve of the serum neopterin concentrations for predicting CAS and its area under curve (AUC) analysis were performed. All statistic analysis was calculated with SPSS 13.0 software system (SPSS Inc., Chicago, IL, USA). A two-sided P-value of less than 0.05 was considered as statistically significant.

3. Results

3.1. Baseline Clinical Characteristics and Biochemical Results

In this research, totally 534 community subjects who had no diseases which corroboratively or potentially affected the function of the immune system including cardiovascular and cerebrovascular disease were eligible after screening of exclusion criterion, with an age of 57.1 ± 5.6 years. The overall baseline clinical characteristics and biochemical results are shown in **Table 2**. Carotid ultrasound revealed 183 (34.3%) subjects with CAS. In these subjects, most were mild stenosis (<50%), only 7 subjects were moderate stenosis (50% - 70%).

3.2. Univariate Comparison between CAS and Control Group

Variables of risk factors of the participants in different groups are shown in **Table 3**. There were significant differences in age, WHR, BMI, history of hypertension, SBP, HDL-C and neopterin level ($P < 0.05$). Neopterin level in the CAS and control group was 5.4 (3.3 - 7.3) nmol/L and 4.6 (3.6 - 5.4) nmol/L respectively (**Figure 1**). However, hs-CRP level in the CAS and control group was 0.91 (0.52 - 5.81) mg/L and 1.02 (0.73 - 7.04) mg/L respectively, and the difference was not significant (**Table 3**).

3.3. Comparison of Neopterin Levels in Different Plaque Characteristics Groups

Neopterin level in the no plaque group, echogenic plaque group and echolucent plaque group were 4.6 (2.8 - 7.8) nmol/L, 4.7 (2.3 - 7.6) nmol/L and 6.0 (3.8 - 8.1)

Table 2. Overall characteristics of 534 community participants.

Age (year)	57.1 ± 5.6
Male, n (%)	158 (29.6%)
WHR	0.88 ± 0.06
BMI (kg/m ²)	23.6 ± 3.3
Smoking, n (%)	80 (15.0%)
Alcohol consumption, n (%)	30 (5.6%)
Hypertension, n (%)	125 (23.4%)
Diabetes, n (%)	44 (8.2%)
Hyperlipidemia, n (%)	141 (26.4%)
SBP (mmHg)	127 ± 17
DBP (mmHg)	79 ± 10
TC (mmol/L)	5.29 ± 0.96
TG (mmol/L)	1.72 ± 1.47
HDL-C (mmol/L)	1.38 ± 0.32
LDL-C (mmol/L)	3.65 ± 0.87
FBG (mmol/L)	5.2 ± 1.2
UA (mmol/L)	295 ± 51
CAS	
Yes, n (%)	183 (34.3%)
Mild	176
Moderate	7
No, n (%)	351 (65.7%)

Table 3. Comparison between CAS and control group (n = 140).

	CAS	control	P
n, (%)	70 (50.0%)	70 (50.0%)	-
Age (year)	60.4 ± 6.4	55.7 ± 5.5	<0.01
Male, n (%)	24 (34.3%)	17 (24.3%)	0.19
WHR	0.90 ± 0.06	0.86 ± 0.06	<0.01
BMI (kg/m ²)	24.2 ± 2.6	22.4 ± 3.2	<0.01
Smoking, n (%)	11 (15.7%)	4 (5.7%)	0.16
Alcohol consumption, n (%)	6 (8.6%)	4 (5.7%)	0.77
Hypertension, n (%)	26 (37.1%)	17 (24.3%)	<0.05
Diabetes mellitus, n (%)	11 (15.7%)	4 (5.7%)	0.16
Hyperlipidemia, n (%)	24 (34.3%)	29 (41.4%)	0.57
SBP (mmHg)	133 ± 15	124 ± 18	<0.01
DBP (mmHg)	80 ± 9	78 ± 11	0.13
TC (mmol/L)	5.34 ± 0.91	5.16 ± 0.99	0.26
TG (mmol/L)	1.70 ± 0.81	1.67 ± 1.40	0.88

Continued

HDL-C (mmol/L)	1.32 ± 0.28	1.45 ± 0.33	<0.05
LDL-C (mmol/L)	3.79 ± 0.84	3.50 ± 0.93	0.06
FBG (mmol/L)	5.3 ± 1.4	5.1 ± 0.8	0.35
UA (mmol/L)	309 ± 99	284 ± 82	0.14
hs-CRP (mg/L)	0.91 (0.52 - 5.81)	1.02 (0.73 - 7.04)	0.36
neopterin (nmol/L)	5.4 (3.3 - 7.3)	4.6 (3.6 - 5.4)	<0.01




Figure 1. Comparison of neopterin levels between CAS and control groups.

nmol/L respectively (**Figure 2**). There were significant differences between no plaque group and echogenic plaque group, no plaque group and echolucent plaque group ($P < 0.05$).

3.4. Correlation between Serum Neopterin and hs-CRP Levels

Figure 3 shows that there was a no significant correlation between serum neopterin and hs-CRP levels ($r = 0.121$, $P = 0.152$)

3.5. Binary Logistic Regression Analysis for the Prediction of CAS

In order to adjust the confounding factors which was significant in univariate analysis, binary logistic regression analysis was performed to investigate the risk factors for CAS (shown in **Table 4**). After multivariate adjusted, neopterin levels remained an independent factor. With per 1.0 nmol/L (approximately 1 IQR) increased, the OR value was 1.84 (95% CI: 1.25 - 2.71, $P < 0.05$).

3.6. ROC Curve

Figure 4 shows the ROC curve of serum neopterin concentrations for the diagnosis of CAS. The AUC was 0.665 ($P < 0.01$). The serum neopterin cutoff value




Figure 2. Comparison of neopterin levels in different plaque characteristics groups.




Figure 3. Correlation between serum neopterin and hs-CRP levels.

Table 4. Binary logistic regression analysis for the prediction of CAS.

	multivariate adjusted OR (95% CI)	P
Age, per 6 increase*	1.72 (1.16 - 2.55)	<0.05
Hypertension (yes vs no)	0.72 (0.26 - 2.00)	0.53
WHR, per 0.06 increase*	1.31 (0.76 - 2.26)	0.33
BMI, per 3 kg/m ² increase*	1.20 (0.72 - 1.99)	0.49
SBP, per 20 mm Hg increase*	1.56 (0.93 - 2.61)	0.09
HDL-C, per 0.3 mmol/L decrease*	0.95 (0.63 - 1.43)	0.80
neopterin, per 1.0 nmol/L increase [▲]	1.84 (1.25 - 2.71)	<0.05

*Approximately 1 SD; [▲]Approximately 1 IQR.




Figure 4. ROC curves of the serum neopterin level for the prediction of CAS.

of 5.1 nmol/L had a sensitivity of 68.6% and specificity of 61.5% in detecting CAS.

4. Discussion

In this community-base study with large sample, we measured circulating serum neopterin levels and investigating the cross-sectional relationship between serum neopterin levels and CAS assessed by ultrasound. Community residents without cardiovascular or cerebrovascular disease were enrolled. Subjects with the diseases which corroboratively or potentially affect the immune system were excluded. Such results were reliable.

Interestingly, some traditional risk factors such as age, WHR, BMI, history of hypertension, SBP, HDL-C were relevant with CAS in our study, which was in accordance with the results of the Tromso Study [20], though these risk factors were not statistically significant after multivariate adjustment in multivariate analysis except of age. Neopterin level remains an independent factor of CAS. The risk of CAS increased by 1.84 times with per 1.0 nmol/L (approximately 1 IQR) increased. Our results, in addition to the previous study, demonstrate that circulating neopterin levels is increased in community population with subclinical carotid atherosclerosis. The results suggested involvement of immune system and the monocyte/macrophage cell activation in the development of CAS.

Ultrasound is the one of the most common techniques used to evaluate CAS [21]. Carotid ultrasound examination is relatively inexpensive, widely available, portable, and noninvasive [21]. In addition to imaging, biochemical findings have important clinical significance [22]. Occurrence and development of CAS are not simply lipid accumulation in the arterial wall but also a process of inflammation reaction [23]. During this process monocyte/macrophage cells occupy vital roles in vascular remodeling [24]. Pro-inflammatory cytokines released by Th1 cells and macrophages are major pro-atherogenic molecules [25].

Inflammatory cytokines involved in vascular inflammation stimulate the generation of endothelial adhesion molecules, proteases, and other mediators, which may enter the circulation in soluble form [25]. The concept of the involvement of inflammation in atherosclerosis has validated the adoption of inflammatory biomarkers for cerebrovascular risk stratification and prediction [26].

There have been many studies showing that neopterin may play an important role in the pathogenesis of atherosclerosis and represent also a marker for cardiovascular risk and cerebrovascular disease [27]. Patients with acute ischemic stroke had significantly higher serum levels of neopterin than controls without ischemic stroke [28]. The level was even higher at 1-year follow-up than at the acute stage, indicating chronic inflammatory activity and continuous macrophage activation in ischemic cerebrovascular diseases [29]. In recent years, several studies had a proved a significant correlation between neopterin levels and carotid IMT in different populations [30], which implied an association with the severity of carotid atherosclerosis. In accordance to the previous studies [31], the presence of complex carotid plaques detected by carotid ultrasound was related to increased circulating levels of neopterin. These findings suggest that neopterin is an important biomarker of plaque instability in carotid atherosclerotic lesions. However, the stenosis in the ICA is currently the benchmark criterion to determine how such disease is to be managed [32]. Research into plaque characteristics and associated inflammation may modify future selection criteria, but, currently, the degree of stenosis remains the cornerstone of management. In this study, we demonstrated that neopterin is associated with CAS and remain an independent risk factor when other confounding factors were adjusted. Hs-CRP is a clinically valuable marker both from atherogenic and infectious point of view. However, in our study, there was neither significant difference in hs-CRP level between the CAS and control groups nor significant correlation between serum neopterin and hs-CRP levels.

This study still provided useful information reinforcing the key roles of inflammatory response in the pathogenesis of CAS and suggested a potential clinical use of neopterin as a serological biochemical marker which served as an alternate approach combining imaging studies in identifying an inflammatory CAS state in subclinical carotid atherosclerosis. Further clinical investigations confirming the direct association between serum neopterin levels and future risk of cerebrovascular events in a manner of cohort study, as well as discussing whether neopterin can be conducive for the decision making of individualized treatment programs such as anti-inflammatory therapy, or can be a parameter in monitoring the substantial benefit during therapeutic follow-up, are warranted.

However, there are still some drawbacks in this study addressed further below. First, the authors should further categorize the subjects based on the severity of CAS. But in our study, the participants were community subclinical subjects, mostly had mild stenosis, only 7 subjects were moderate stenosis. For this reason, it is unrealistic to further categorize the patients based on the severity of

CAS. Even though a flaw it was, our study revealed that vascular inflammatory reaction has been prominent even when the carotid artery is in the primary stage with mild stenosis. Moreover, the authors did not study all of the subjects. However, random sampling was used in the study, so the sample is representative.

5. Conclusion

Our findings demonstrate that circulating neopterin level is increased in sub-clinical carotid atherosclerosis population with CAS and reinforce the key roles of inflammatory response in the pathogenesis.

Acknowledgements

Grant support: The present study was partially supported by Projects of Innovation Collaborative Research of Guangzhou Municipal Science and Technology projects (2014Y2-00502).

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

- [1] Mukherjee, D. and Patil, C.G. (2011) Epidemiology and the Global Burden of Stroke. *World Neurosurgery*, **76**, S85-S90. <https://doi.org/10.1016/j.wneu.2011.07.023>
- [2] Mathiesen, E.B. and Johnsen, S.H. (2009) Ultrasonographic Measurements of Sub-clinical Carotid Atherosclerosis in Prediction of Ischemic Stroke. *Acta Neurologica Scandinavica. Supplementum*, **189**, 68-72. <https://doi.org/10.1111/j.1600-0404.2009.01210.x>
- [3] Ross, R. (1999) Atherosclerosis—An Inflammatory Disease. *New England Journal of Medicine*, **340**, 115-126. <https://doi.org/10.1056/NEJM199901143400207>
- [4] Hankey, G.J., *et al.* (2000) Five-Year Survival after First-Ever Stroke and Related Prognostic Factors in the Perth Community Stroke Study. *Stroke*, **31**, 2080-2086. <https://doi.org/10.1161/01.STR.31.9.2080>
- [5] Huber, C., *et al.* (1984) Immune Response-Associated Production of Neopterin. Release from Macrophages Primarily under Control of Interferon-Gamma. *Journal of Experimental Medicine*, **160**, 310-316. <https://doi.org/10.1084/jem.160.1.310>
- [6] Murr, C., *et al.* (2002) Neopterin as a Marker for Immune System Activation. *Current Drug Metabolism*, **3**, 175-187. <https://doi.org/10.2174/1389200024605082>
- [7] Zierler, R. and Strandness, D. (1987) Noninvasive Dynamic and Real-Time Assessment of Extracranial Cerebrovasculature, in *Cerebral Blood Flow: Physiologic and Clinical Aspects*. McGraw-Hill, New York, 311.
- [8] Chambless, L.E., *et al.* (2000) Carotid Wall Thickness Is Predictive of Incident Clinical Stroke: The Atherosclerosis Risk in Communities (ARIC) Study. *American Journal of Epidemiology*, **151**, 478-487. <https://doi.org/10.1093/oxfordjournals.aje.a010233>

- [9] Ebrahim, S., et al. (1999) Carotid Plaque, Intima Media Thickness, Cardiovascular Risk Factors, and Prevalent Cardiovascular Disease in Men and Women: The British Regional Heart Study. *Stroke*, **30**, 841-850. <https://doi.org/10.1161/01.STR.30.4.841>
- [10] Schulte-Altendorneburg, G., et al. (2000) Preoperative B-Mode Ultrasound Plaque Appearance Compared with Carotid Endarterectomy Specimen Histology. *Acta Neurologica Scandinavica*, **101**, 188-194. <https://doi.org/10.1034/j.1600-0404.2000.101003188.x>
- [11] Knox, R.A., Breslau, P.J. and Strandness, D.J. (1982) A Simple Parameter for Accurate Detection of Severe Carotid Disease. *British Journal of Surgery*, **69**, 230-233. <https://doi.org/10.1002/bjs.1800690421>
- [12] Joakimsen, O., et al. (1999) Age and Sex Differences in the Distribution and Ultrasound Morphology of Carotid Atherosclerosis: The Tromso Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **19**, 3007-3013. <https://doi.org/10.1161/01.ATV.19.12.3007>
- [13] Makris, G.C., et al. (2011) Three-Dimensional Ultrasound Imaging for the Evaluation of Carotid Atherosclerosis. *Atherosclerosis*, **219**, 377-383. <https://doi.org/10.1016/j.atherosclerosis.2011.05.006>
- [14] Hermus, L., et al. (2010) Carotid plaque Formation and Serum Biomarkers. *Atherosclerosis*, **213**, 21-29. <https://doi.org/10.1016/j.atherosclerosis.2010.05.013>
- [15] Baldassarre, D., et al. (2008) Carotid Intima-Media Thickness and Markers of Inflammation, Endothelial Damage and Hemostasis. *Annals of Medicine*, **40**, 21-44. <https://doi.org/10.1080/07853890701645399>
- [16] Boyle, J.J. (2005) Macrophage Activation in Atherosclerosis: Pathogenesis and Pharmacology of Plaque Rupture. *Current Vascular Pharmacology*, **3**, 63-68. <https://doi.org/10.2174/1570161052773861>
- [17] Hansson, G.K., Robertson, A.K. and Soderberg-Naucler, C. (2006) Inflammation and Atherosclerosis. *Annual Review of Pathology*, **1**, 297-329. <https://doi.org/10.1146/annurev.pathol.1.110304.100100>
- [18] Packard, R.R. and Libby, P. (2008) Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction. *Clinical Chemistry*, **54**, 24-38. <https://doi.org/10.1373/clinchem.2007.097360>
- [19] Fuchs, D., et al. (2009) The Role of Neopterin in Atherogenesis and Cardiovascular Risk Assessment. *Current Medicinal Chemistry*, **16**, 4644-4653. <https://doi.org/10.2174/092986709789878247>
- [20] Cojocaru, I.M., et al. (2007) Detection of Neopterin as Parameter of Potential Monocyte Activation in Patients with Acute Ischemic Stroke. *Romanian Journal of Internal Medicine*, **45**, 365-369.
- [21] Anwaar, I., et al. (1999) Increasing Plasma Neopterin and Persistent Plasma Endothelin during Follow-Up after Acute Cerebral Ischemia. *Angiology*, **50**, 1-8. <https://doi.org/10.1177/000331979905000101>
- [22] Erten, Y., et al. (2005) Association between Neopterin and Carotid Intima-Media Thickness in Hemodialysis Patients. *Nephron Clinical Practice*, **101**, c134-c138.
- [23] Sugioka, K., et al. (2010) Neopterin and Atherosclerotic Plaque Instability in Coronary and Carotid Arteries. *Journal of Atherosclerosis and Thrombosis*, **17**, 1115-1121. <https://doi.org/10.5551/jat.4606>
- [24] Gray, C., et al. (2015) The Implications of Different Criteria for Grading Carotid Artery Stenosis by Duplex Ultrasound. *Journal of Clinical Ultrasound*, **43**, 563-566.

- <https://doi.org/10.1002/jcu.22285>
- [25] White, H., *et al.* (2005) Ischemic Stroke Subtype Incidence among Whites, Blacks, and Hispanics: The Northern Manhattan Study. *Circulation*, **111**, 1327-1331. <https://doi.org/10.1161/01.CIR.0000157736.19739.D0>
- [26] Petty, G.W., *et al.* (1999) Ischemic Stroke Subtypes: a Population-based Study of Incidence and Risk factors. *Stroke*, **30**, 2513-2516. <https://doi.org/10.1161/01.STR.30.12.2513>
- [27] Grubb, R.J., *et al.* (1998) Importance of Hemodynamic Factors in the Prognosis of Symptomatic Carotid Occlusion. *JAMA*, **280**, 1055-1060. <https://doi.org/10.1001/jama.280.12.1055>
- [28] Tsiskaridze, A., *et al.* (2001) Stroke with Internal Carotid Artery Stenosis. *Archives of Neurolog*, **58**, 605-609. <https://doi.org/10.1001/archneur.58.4.605>
- [29] Sabeti, S., *et al.* (2005) Prognostic Impact of Fibrinogen in Carotid Atherosclerosis: Nonspecific Indicator of Inflammation or Independent Predictor of Disease Progression? *Stroke*, **36**, 1400-1404. <https://doi.org/10.1161/01.STR.0000169931.96670.fc>
- [30] Alvarez, G.B., *et al.* (2003) High-Sensitivity C-Reactive Protein in High-grade Carotid Stenosis: Risk Marker for Unstable Carotid Plaque. *Journal of Vascular Surgery*, **38**, 1018-1024. [https://doi.org/10.1016/S0741-5214\(03\)00709-2](https://doi.org/10.1016/S0741-5214(03)00709-2)
- [31] Garcia-Moll, X., *et al.* (2000) Increased Serum Neopterin: A Marker of Coronary Artery Disease Activity in Women. *Heart*, **83**, 346-350. <https://doi.org/10.1136/heart.83.3.346>
- [32] Scandinavian Simvastatin Study Group (1994) Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*, **344**, 1383-1389.

Abbreviations

AUC, area under curve; BMI, Body mass index; CAA, Carotid artery atherosclerosis; CAS, carotid artery stenosis; DBP, diastolic blood pressure; EDV, end diastolic velocity; ELISA, enzyme-linked immunosorbent assay; FBG, fasting blood glucose; HDL-C, high density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reaction protein; ICA, internal carotid artery; IMT, intima-media thickness; IQR, interquartile range; LDL-C, low density lipoprotein cholesterol; OR, odds ratio; PSV, peak systolic velocity; ROC, receiver operating characteristic; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglyceride; UA, uric acid; WHR, waist hip ratio.